Waqaas Al-Siddiq, Co-founder and CEO of biotricity was interviewed at the conference and gave a brief overview of the company and its innovative approach towards the current chronic care market.
If you missed the live webcast, the presentation is available for replay below and also at the Gateway Conference website at http://wsw.com/webcast/liolios2/btcy.[/vc_column_text][vc_single_image media=”2686″ media_width_percent=”100″][vc_column_text]Biotricity is focused on delivering ground-breaking, clinical-grade remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. The company’s flagship product called Bioflux, which is currently in development, is a mobile cardiac telemetry (MCT) solution that is designed to enable physicians to remotely monitor and diagnose cardiovascular disease (CVD) and coronary heart disease by detecting arrhythmias.[/vc_column_text][vc_empty_space empty_h=”2″][/vc_column][/vc_row]
